Supply ACAM2000 smallpox vaccine
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Jul 2024
- Due
- 31 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A contract modification valued at $99.9 million to supply ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) this year.”
What we found
Evidence strength A What the grades mean
Emergent delivered ACAM2000 vaccine under the $99.9 million contract by December 31, 2024, as evidenced by September 2024 delivery reporting.
-
A Emergent BioSolutions Inc. - Form 10-Q - FY2024
“Smallpox MCM sales increased $108.0 million to $132.7 million for the three months ended September 30, 2024. The increase was primarily due to timing of USG purchases of ACAM2000® and VIGIV.” ✓ confirmed on the page
-
A Emergent BioSolutions Inc. - Form 10-K - FY2024
“On June 28, 2024, Emergent Product Development Gaithersburg Inc., received a contract modification from the ASPR exercising and funding the fifth contract term extension options (the "Fifth Option Exercise") for Emergent to supply ACAM2000® to the SNS. The Fifth Option Exercise is valued at approxim” ✓ confirmed on the page
-
B Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025
“To date in 2024, customer orders of nearly $210 million have been delivered for ACAM2000® and VIGIV.” not found on the page
Checked 7 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Supply
- Deliverable
- ACAM2000 smallpox vaccine
- Amount
- USD 99.9
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-EBS-002494 · Corrections policy